AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN...